Comments
Shares of Dr. Reddy’s Laboratories Ltd today gained 1.1 per cent as the company has entered into a partnership with Hetero to distribute and market a drug used in the treatment of Hepatitis C in India.
“We expect the drug to be meaningful revenue driver for Dr. Reddy’s,’’ says Hitesh Mahida, research analyst, Antique Stock Broking Ltd.
He adds that the drug may enjoy operating margins of 25-30 per cent.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.